Establishment of animal model for the analysis of cancer cell metastasis during radiotherapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Park, Jong K ^a   Jang, Su J ^a   Kang, Sung W ^a   Park, Sunhoo ^a   Hwang, Sang Gu ^a   Kim, Wun Jae ^b   Kang, Joo H ^a   Um, Hong Duck ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

Author keywords

Ionizing Radiation; Animal model; Bioluminescence imaging; Cancer; Epithelial mesenchymal transition; Metastasis

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EX VIVO STUDY; GAMMA IRRADIATION; GLIOMA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; IONIZING RADIATION; METASTASIS; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; LUMINESCENCE; NEOPLASMS; PATHOLOGY; PROCEDURES; RAT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOMA; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIATION, IONIZING; RADIOTHERAPY; RATS;

EID: 84865979748     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-153     Document Type: Article

References (57)

1. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006, 127(4):679-695. 10.1016/j.cell.2006.11.001, 17110329.
2. Weber GF. Molecular mechanisms of metastasis. Cancer Lett 2008, 270(2):181-190. 10.1016/j.canlet.2008.04.030, 18522865.
3. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3(5):362-374. 10.1038/nrc1075, 12724734.
4. Pavelic SK, Sedic M, Bosnjak H, Spaventi S, Pavelic K. Metastasis: new perspectives on an old problem. Mol Cancer 2011, 10:22. 10.1186/1476-4598-10-22, 3052211, 21342498.
5. Box C, Rogers SJ, Mendiola M, Eccles SA. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol 2010, 20(3):128-138. 10.1016/j.semcancer.2010.06.004, 20599506.
6. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010, 29(2):351-378. 10.1007/s10555-010-9225-4, 20386957.
7. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4(11):891-899. 10.1038/nrc1478, 15516961.
8. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16(24):5928-5935. 10.1158/1078-0432.CCR-10-1360, 3005023, 20962028.
9. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65(2):613-621.
10. Sierra A. Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist Updat 2005, 8(4):247-57. 10.1016/j.drup.2005.07.001, 16095951.
11. Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997, 9(5):701-706. 10.1016/S0955-0674(97)80124-X, 9330874.
12. Glinskii AB, Smith BA, Jiang P, Li XM, Yang M, Hoffman RM, Glinsky GV. Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models. Cancer Res 2003, 63(14):4239-4243.
13. Geiger TR, Peeper DS. The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 2005, 65(16):7033-7036. 10.1158/0008-5472.CAN-05-0709, 16103047.
14. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Res 2005, 65(24):11230-11235. 10.1158/0008-5472.CAN-05-2763, 2367317, 16357123.
15. Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol 2010, 36(1):181-192.
16. Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Um HD. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006, 66(10):4991-4995. 10.1158/0008-5472.CAN-05-4254, 16707418.
17. Chung T-W, Lee Y-C, Kim C-H. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3 K/AKT pathways: Involvement of invasive potential. FASEB J 2004, 18:1123-1125.
18. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172(7):973-981. 10.1083/jcb.200601018, 2063755, 16567498.
19. Yang J, Weinberg RA. Epithelial-Mesenchymal Transition: at the Crossroads of Development and Tumor Metastasis. Dev Cell 2008, 14:818-829. 10.1016/j.devcel.2008.05.009, 18539112.
20. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890. 10.1016/j.cell.2009.11.007, 19945376.
21. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7(6):415-428. 10.1038/nrc2131, 17508028.
22. Ho JN, Kang GY, Lee SS, Kim J, Bae IH, Hwang SG, Um HD. Bcl-XL and STAT3 mediate malignant actions of gamma-irradiation in lung cancer cells. Cancer Sci 2010, 101(6):1417-1423. 10.1111/j.1349-7006.2010.01552.x, 20331635.
23. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007, 14(12):3629-3637. 10.1245/s10434-007-9583-5, 17909916.
24. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006, 118(2):290-301. 10.1002/ijc.21355, 16080193.
25. Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis 2004, 21(3):201-212.
26. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010, 101(2):293-299. 10.1111/j.1349-7006.2009.01419.x, 19961486.
27. Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25(53):7009-7018. 10.1038/sj.onc.1209706, 16732316.
28. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH, Hong SI. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006, 66(17):8511-8519. 10.1158/0008-5472.CAN-05-4340, 16951163.
29. Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008, 44(1):1-13. 10.1016/j.freeradbiomed.2007.09.022, 2266095, 17967430.
30. Piva R, Belardo G, Santoro MG. NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 2006, 8(3-4):478-486.
31. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009, 108(3):180-194. 10.1016/S0929-6646(09)60051-6, 19293033.
32. Kraus AC, Ferber I, Bachmann SO, Specht H, Wimmel A, Gross MW, Schlegel J, Suske G, Schuermann M. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21(57):8683-8695. 10.1038/sj.onc.1205939, 12483521.
33. Kim EM, Yang HS, Kang SW, Ho JN, Lee SB, Um HD. Amplification of the gamma-irradiation-induced cell death pathway by reactive oxygen species in human U937 cells. Cell Signal 2008, 20(5):916-924. 10.1016/j.cellsig.2008.01.002, 18262755.
34. Park JK, Chung YM, Kim BG, Yoo YA, Yang BS, Kim JS, Yoo YD. N'-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells. Mol Cancer Ther 2004, 3(4):403-407.
35. Jang SJ, Kang JH, Kim KI, Lee TS, Lee YJ, Lee KC, Woo KS, Chung WS, Kwon HC, Ryu CJ, Choi TH, Choi CW, Lim SM, Cheon GJ. Application of bioluminescence imaging to therapeutic intervention of herpes simplex virus type I - Thymidine kinase/ganciclovir in glioma. Cancer Letts 2010, 297(1):84-90.
36. von Essen CF. Radiation enhancement of metastasis: a review. Clin Exp Metastasis 1991, 9(2):77-104. 10.1007/BF01756381, 2032423.
37. Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 2002, 310(3):257-270. 10.1007/s00441-002-0651-7, 12457224.
38. Jung JW, Hwang SY, Hwang JS, Oh ES, Park S, Han IO. Ionizing radiation induces changes associated with epithelial-mesenchymal transdifferentiation and increased cell motility of A549 lung epithelial cells. Eur J Cancer 2007, 43(7):1214-1224. 10.1016/j.ejca.2007.01.034, 17379505.
39. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001, 61(5):2207-2211.
40. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003, 17(5):545-580. 10.1101/gad.1047403, 12629038.
41. Contag CH, Jenkins D, Contag PR, Negrin RS. Use of Reporter Genes for Optical Measurements of Neoplastic Disease In vivo. Neoplasia 2000, 2(1-2):41-52. 1550286, 10933067.
42. Viviani VR. The origin, diversity, and structure function relationships of insect luciferases. Cell Mol Life Sci 2002, 59(11):1833-1850. 10.1007/PL00012509, 12530517.
43. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2(6):442-454. 10.1038/nrc822, 12189386.
44. Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, Ko S, Hui WM, Yueng YH, Wong J. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 2003, 21(12):2288-2293. 10.1200/JCO.2003.08.078, 12805328.
45. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995, 71(3):614-616. 10.1038/bjc.1995.119, 2033614, 7880746.
46. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008, 99(9):1476-1483. 10.1038/sj.bjc.6604713, 2579693, 18854838.
47. Utsunomiya T, Yao T, Masuda K, Tsuneyoshi M. Vimentin-positive adenocarcinomas of the stomach: co-expression of vimentin and cytokeratin. Histopathology 1996, 29(6):507-516. 10.1046/j.1365-2559.1996.d01-538.x, 8971557.
48. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005, 65(14):5996-6000. 10.1158/0008-5472.CAN-05-0699, 16024596.
49. Pawelek JM, Chakraborty AK. The cancer cell-leukocyte fusion theory of metastasis. Adv Cancer Res 2008, 101:397-444.
50. Huysentruyt LC, Seyfried TN. Perspectives on the mesenchymal origin of metastatic cancer. Cancer Metastasis Rev 2010, 29(4):695-707. 10.1007/s10555-010-9254-z, 2962789, 20839033.
51. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res 2011, 71(4):1497-1505. 10.1158/0008-5472.CAN-10-3223, 3079548, 21303980.
52. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003, 5(1):59-63. 10.1038/ncb898, 12483219.
53. Adès L, Guardiola P, Sociè G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev 2002, 16(2):135-146. 10.1054/blre.2002.0010, 12127957.
54. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer 2009, 125(8):1826-1831. 10.1002/ijc.24506, 19582880.
55. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007, 67(24):11687-11695. 10.1158/0008-5472.CAN-07-1406, 18089798.
56. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007, 117(5):1305-1313. 10.1172/JCI30740, 1838926, 17415413.
57. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010, 9(10):804-820. 10.1038/nrd3266, 20885411.